Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 230

1.

ATP binding cassette multidrug transporters limit the anti-HIV activity of zidovudine and indinavir in infected human macrophages.

Jorajuria S, Dereuddre-Bosquet N, Becher F, Martin S, Porcheray F, Garrigues A, Mabondzo A, Benech H, Grassi J, Orlowski S, Dormont D, Clayette P.

Antivir Ther. 2004 Aug;9(4):519-28.

PMID:
15456083
2.

Non-steroidal anti-inflammatory drugs increase the antiretroviral activity of nucleoside reverse transcriptase inhibitors in HIV type-1-infected T-lymphocytes: role of multidrug resistance protein 4.

Clemente MI, Alvarez S, Serramía MJ, Turriziani O, Genebat M, Leal M, Fresno M, Muñoz-Fernández MA.

Antivir Ther. 2009;14(8):1101-11. doi: 10.3851/IMP1468.

PMID:
20032540
3.
4.

Effect of protease inhibitor-containing regimens on lymphocyte multidrug resistance transporter expression.

Ford J, Meaden ER, Hoggard PG, Dalton M, Newton P, Williams I, Khoo SH, Back DJ.

J Antimicrob Chemother. 2003 Sep;52(3):354-8. Epub 2003 Aug 13.

PMID:
12917239
5.

Anti-HIV effects of chloroquine: inhibition of viral particle glycosylation and synergism with protease inhibitors.

Savarino A, Lucia MB, Rastrelli E, Rutella S, Golotta C, Morra E, Tamburrini E, Perno CF, Boelaert JR, Sperber K, Cauda R.

J Acquir Immune Defic Syndr. 2004 Mar 1;35(3):223-32.

PMID:
15076236
6.

Efficacy of zidovudine compared to stavudine, both in combination with lamivudine and indinavir, in human immunodeficiency virus-infected nucleoside-experienced patients with no prior exposure to lamivudine, stavudine, or protease inhibitors (novavir trial).

Joly V, Flandre P, Meiffredy V, Brun-Vezinet F, Gastaut JA, Goujard C, Remy G, Descamps D, Ruffault A, Certain A, Aboulker JP, Yeni P; Novavir Study Group.

Antimicrob Agents Chemother. 2002 Jun;46(6):1906-13.

7.

P-glycoprotein, multidrug resistance-associated proteins and human organic anion transporting polypeptide influence the intracellular accumulation of atazanavir.

Janneh O, Anwar T, Jungbauer C, Kopp S, Khoo SH, Back DJ, Chiba P.

Antivir Ther. 2009;14(7):965-74. doi: 10.3851/IMP1399.

PMID:
19918100
8.

Antiviral activity of HIV type 1 protease inhibitors nelfinavir and indinavir in vivo is not influenced by P-glycoprotein activity on CD4+ T cells.

Sankatsing SU, Cornelissen M, Kloosterboer N, Crommentuyn KM, Bosch TM, Mul FP, Jurriaans S, Huitema AD, Beijnen JH, Lange JM, Prins JM, Schuitemaker H.

AIDS Res Hum Retroviruses. 2007 Jan;23(1):19-27.

PMID:
17263628
9.

Breast cancer resistance protein (BCRP/ABCG2) induces cellular resistance to HIV-1 nucleoside reverse transcriptase inhibitors.

Wang X, Furukawa T, Nitanda T, Okamoto M, Sugimoto Y, Akiyama S, Baba M.

Mol Pharmacol. 2003 Jan;63(1):65-72.

10.

The effects of protease inhibitors and nonnucleoside reverse transcriptase inhibitors on p-glycoprotein expression in peripheral blood mononuclear cells in vitro.

Chandler B, Almond L, Ford J, Owen A, Hoggard P, Khoo S, Back D.

J Acquir Immune Defic Syndr. 2003 Aug 15;33(5):551-6.

PMID:
12902797
11.

Triple nucleoside treatment with abacavir plus the lamivudine/zidovudine combination tablet (COM) compared to indinavir/COM in antiretroviral therapy-naïve adults: results of a 48-week open-label, equivalence trial (CNA3014).

Vibhagool A, Cahn P, Schechter M, Smaill F, Soto-Ramirez L, Carosi G, Montroni M, Pharo CE, Jordan JC, Thomas NE, Pearce G.

Curr Med Res Opin. 2004 Jul;20(7):1103-14.

PMID:
15265255
12.

Evaluation of HIV protease and nucleoside reverse transcriptase inhibitors on proliferation, necrosis, apoptosis in intestinal epithelial cells and electrolyte and water transport and epithelial barrier function in mice.

Braga Neto MB, Aguiar CV, Maciel JG, Oliveira BM, Sevilleja JE, Oriá RB, Brito GA, Warren CA, Guerrant RL, Lima AA.

BMC Gastroenterol. 2010 Aug 11;10:90. doi: 10.1186/1471-230X-10-90.

13.

P-Glycoprotein and transporter MRP1 reduce HIV protease inhibitor uptake in CD4 cells: potential for accelerated viral drug resistance?

Jones K, Bray PG, Khoo SH, Davey RA, Meaden ER, Ward SA, Back DJ.

AIDS. 2001 Jul 27;15(11):1353-8.

PMID:
11504956
14.

Expression levels of MDR1, MRP1, MRP4, and MRP5 in peripheral blood mononuclear cells from HIV infected patients failing antiretroviral therapy.

Turriziani O, Gianotti N, Falasca F, Boni A, Vestri AR, Zoccoli A, Lazzarin A, Antonelli G.

J Med Virol. 2008 May;80(5):766-71. doi: 10.1002/jmv.21152.

PMID:
18360888
15.

Assessment of active transport of HIV protease inhibitors in various cell lines and the in vitro blood--brain barrier.

van der Sandt IC, Vos CM, Nabulsi L, Blom-Roosemalen MC, Voorwinden HH, de Boer AG, Breimer DD.

AIDS. 2001 Mar 9;15(4):483-91.

PMID:
11242145
17.

The protease inhibitor ritonavir inhibits the functional activity of the multidrug resistance related-protein 1 (MRP-1).

Olson DP, Scadden DT, D'Aquila RT, De Pasquale MP.

AIDS. 2002 Sep 6;16(13):1743-7.

PMID:
12218384
18.

Multidrug resistance protein (MRP) 4- and MRP 5-mediated efflux of 9-(2-phosphonylmethoxyethyl)adenine by microglia.

Dallas S, Schlichter L, Bendayan R.

J Pharmacol Exp Ther. 2004 Jun;309(3):1221-9. Epub 2004 Feb 4.

19.

Up-regulation of P-glycoprotein by HIV protease inhibitors in a human brain microvessel endothelial cell line.

Zastre JA, Chan GN, Ronaldson PT, Ramaswamy M, Couraud PO, Romero IA, Weksler B, Bendayan M, Bendayan R.

J Neurosci Res. 2009 Mar;87(4):1023-36. doi: 10.1002/jnr.21898.

PMID:
18855943
20.

Inhibition of P-glycoprotein by HIV protease inhibitors increases intracellular accumulation of berberine in murine and human macrophages.

Zha W, Wang G, Xu W, Liu X, Wang Y, Zha BS, Shi J, Zhao Q, Gerk PM, Studer E, Hylemon PB, Pandak WM Jr, Zhou H.

PLoS One. 2013;8(1):e54349. doi: 10.1371/journal.pone.0054349. Epub 2013 Jan 23.

Supplemental Content

Support Center